A randomized controlled trial of metastases-directed treatment in patients with metastatic prostate cancer using stereotactic body irradiation : A GETUG-AFU trial
Copyright © 2017 Société française de radiothérapie oncologique (SFRO). Published by Elsevier SAS. All rights reserved..
The goal of treatment of metastatic prostate cancer remains palliation. The oligometastatic state could be the right time to intensify therapy by introducing metastases directed treatments. The aim of this trial was to evaluate the benefit of radiotherapy to all macroscopic metastatic sites and to the primary disease in patients with hormone sensitive oligometastatic prostate cancer.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique - 21(2017), 6-7 vom: 09. Okt., Seite 491-494 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Rôle de la radiothérapie ablative des métastases chez les patients atteints de cancer de la prostate oligométastatique hormonosensible : un essai du Groupe d’étude des tumeurs urogénitales et de l’Association française d’urologie |
|---|
| Beteiligte Personen: |
Blanchard, P [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cancer |
|---|
| Anmerkungen: |
Date Completed 05.10.2017 Date Revised 05.10.2017 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.canrad.2017.06.007 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM275413160 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM275413160 | ||
| 003 | DE-627 | ||
| 005 | 20231225005627.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2017 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.1016/j.canrad.2017.06.007 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0918.xml |
| 035 | |a (DE-627)NLM275413160 | ||
| 035 | |a (NLM)28869198 | ||
| 035 | |a (PII)S1278-3218(17)30178-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Blanchard, P |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A randomized controlled trial of metastases-directed treatment in patients with metastatic prostate cancer using stereotactic body irradiation |b A GETUG-AFU trial |
| 246 | 3 | 3 | |a Rôle de la radiothérapie ablative des métastases chez les patients atteints de cancer de la prostate oligométastatique hormonosensible : un essai du Groupe d’étude des tumeurs urogénitales et de l’Association française d’urologie |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.10.2017 | ||
| 500 | |a Date Revised 05.10.2017 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2017 Société française de radiothérapie oncologique (SFRO). Published by Elsevier SAS. All rights reserved. | ||
| 520 | |a The goal of treatment of metastatic prostate cancer remains palliation. The oligometastatic state could be the right time to intensify therapy by introducing metastases directed treatments. The aim of this trial was to evaluate the benefit of radiotherapy to all macroscopic metastatic sites and to the primary disease in patients with hormone sensitive oligometastatic prostate cancer | ||
| 650 | 4 | |a Clinical Trial, Phase III | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Cancer | |
| 650 | 4 | |a Metastasis | |
| 650 | 4 | |a Métastase | |
| 650 | 4 | |a Prostate | |
| 650 | 4 | |a Radiothérapie stéréotaxique | |
| 650 | 4 | |a Stereotactic radiotherapy | |
| 700 | 1 | |a Foulon, S |e verfasserin |4 aut | |
| 700 | 1 | |a Louvel, G |e verfasserin |4 aut | |
| 700 | 1 | |a Habibian, M |e verfasserin |4 aut | |
| 700 | 1 | |a Fizazi, K |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique |d 1998 |g 21(2017), 6-7 vom: 09. Okt., Seite 491-494 |w (DE-627)NLM092193420 |x 1769-6658 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2017 |g number:6-7 |g day:09 |g month:10 |g pages:491-494 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.canrad.2017.06.007 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2017 |e 6-7 |b 09 |c 10 |h 491-494 | ||